1. Home
  2. KTTA vs BBAI.WS Comparison

KTTA vs BBAI.WS Comparison

Compare KTTA & BBAI.WS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

SELL

Current Price

$0.48

Market Cap

15.6M

Sector

Health Care

ML Signal

SELL

BBAI.WS

BigBear.ai Inc. Redeemable Warrants each exercisable for one share of Common Stock at an exercise price of $11.50 per share

N/A

Current Price

$0.01

Market Cap

16.2M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
KTTA
BBAI.WS
Founded
2020
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
15.6M
16.2M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
KTTA
BBAI.WS
Price
$0.48
$0.01
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 1.4M
114.5K
Earning Date
11-13-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
★ 77.07
N/A
EPS
N/A
★ N/A
Revenue
★ $486,559.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 3130.37
N/A
52 Week Low
$0.32
$0.00
52 Week High
$2.06
$0.03

Technical Indicators

Market Signals
Indicator
KTTA
BBAI.WS
Relative Strength Index (RSI) 49.53 16.99
Support Level $0.42 N/A
Resistance Level $0.57 $0.02
Average True Range (ATR) 0.08 0.01
MACD -0.00 -0.00
Stochastic Oscillator 48.59 13.42

Price Performance

Historical Comparison
KTTA
BBAI.WS

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Share on Social Networks: